01—Abstract
Summary
Summary of the 10-Q filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals Inc. reported strong financial results for the third quarter and the first nine months of 2025, demonstrating significant year-over-year growth in product revenues.
Total revenues reached $3.1 billiona for the quarter, an 11% increase, and $8.8 billion for the nine-month period, up 9%, driven primarily by the sustained demand for their cystic fibrosis (CF) treatments, particularly TRIKAFTA/KAFTRIO, and early contributions from new product launches. The company also highlighted progress in expanding its therapeutic areas beyond CF, with notable advancements in its pipeline for sickle cell disease (SCD), beta-thalassemia (TDT), acute pain, and various kidney and autoimmune diseases. The acquisition of Alpine Immune Sciences in May 2024 continues to be a significant factor, contributing to R&D expenses but also bringing promising candidates like povetacicept into the pipeline.
Despite increased operating costs, including R&D and SG&A expenses, driven by commercial investments and pipeline expansion, Vertex maintained robust profitability. The company ended the period with a healthy cash position of $12.0 billionb, reflecting strong operating cash flow.
02—Key points
Key Highlights
- Product revenues increased by 11% year-over-year to $3.1 billion in Q3 2025, driven by strong demand for TRIKAFTA/KAFTRIO and new product contributions.
- Total revenues grew 9% for the nine-month period ending September 30, 2025, reaching $8.8 billion.
- Net income for the nine months was $2.8 billion, a significant turnaround from a net loss of $1.4 billion in the prior year period, largely due to a substantial acquired in-process R&D charge in 2024 related to the Alpine acquisition.
- The company has a robust pipeline, with significant progress reported in clinical trials for its SCD/TDT therapies, Type 1 Diabetes programs, and kidney disease treatments.
- Cash, cash equivalents, and marketable securities increased to $12.0 billion as of September 30, 2025, up from $11.2 billion at the end of 2024, supported by strong operating cash flows.
- Vertex repurchased approximately $1.9 billion of its common stock in the first nine months of 2025 under its new $4.0 billion share repurchase program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Vertex Pharmaceuticals Inc kept $0.35.
- Revenue$3.08B100.0%
- Cost of revenue−$414.8M13.5%
- Gross profit$2.66B86.5%
- Operating costs−$1.48B48.0%
- Operating income$1.19B38.6%
- Interest, other & tax−$103.3M3.4%
- Net income$1.08B35.2%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed November 4, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $3.08B$2.77B | +11.0% |
| Cost of Revenue | $414.80M$392.60M | +5.7% |
| Gross Profit | $2.66B$2.38B | +11.9% |
| SG&A Expenses | $445.10M$371.80M | +19.7% |
| Operating Expenses | $1.89B$1.66B | +14.2% |
| Operating Income | $1.19B$1.12B | +6.3% |
| Net Income | $1.08B$1.05B | +3.6% |
| EPS (Basic) | $4.24$4.05 | +4.7% |
| EPS (Diluted) | $4.20$4.01 | +4.7% |
| Shares Outstanding (Basic) | 255.60M258.00M | −0.9% |
| Shares Outstanding (Diluted) | 257.60M261.00M | −1.3% |
05—Questions
Frequently Asked Questions
What drove the significant increase in net income for the nine months ended September 30, 2025, compared to the same period in 2024?
The substantial increase in net income from a loss of $1.4 billion to a gain of $2.8 billion for the nine months ended September 30, 2025, is largely attributable to the absence of a significant $4.4 billion acquired in-process R&D expense in 2025, which was recognized in the nine months ended September 30, 2024, related to the acquisition of Alpine Immune Sciences, Inc. This year's results reflect strong revenue growth and operational efficiency.
How is Vertex diversifying its revenue streams beyond cystic fibrosis?
Vertex is actively expanding its therapeutic reach. The company is advancing its pipeline in areas such as sickle cell disease and beta-thalassemia with CASGEVY, acute pain with JOURNAVX (which has seen over 300,000 prescriptions since March), and has promising candidates for IgA nephropathy, APOL1-mediated kidney disease, and Type 1 Diabetes. Partnerships and out-licensing agreements, such as those for povetacicept in Asian markets, also contribute to revenue diversification.
What is the status of the royalty dispute regarding ALYFTREK?
Royalty Pharma plc (RP), to whom the Cystic Fibrosis Foundation (CFF) assigned its rights, has initiated a confidential arbitration alleging that the royalty burden on ALYFTREK is approximately 8%, differing from Vertex's position of 4%. Vertex believes RP's claim is contrary to the CFF Agreement and intends to vigorously defend its position.
What is the company's strategy regarding capital allocation, particularly share repurchases and future investments?
Vertex has a strong liquidity position with $12.0 billion in cash, cash equivalents, and marketable securities. The company recently authorized a $4.0 billion share repurchase program, with approximately $3.5 billion remaining as of September 30, 2025. This demonstrates confidence in future cash generation, which is expected to fund operations, R&D investments, potential milestone payments, and shareholder returns.
06—Continue